ERNA
Ernexa Therapeutics Inc.
Price Chart
Latest Quote
$6.20
+0.31 (+5.26%)
Current Price
| Previous Close | $5.89 |
| Open | $6.04 |
| Day High | $6.20 |
| Day Low | $5.62 |
| Volume | 34,710 |
Stock Information
| Shares Outstanding | 1.17M |
| Total Debt | $389K |
| Cash Equivalents | $9.18M |
| Net Income | $-11.40M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $7.23M |
| P/E Ratio | 0.01 |
| EPS (TTM) | $1216.21 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-1.56M |
| Income | $-11.40M |
| Book/sh | $5.88 |
| Cash/sh | $7.87 |
| Employees | 5 |
Financial Ratios
| Quick Ratio | 2.68 |
| Current Ratio | 2.89 |
| Debt/Eq | 5.67 |
Returns & Margins
| ROA | -81.20% |
| ROE | -2505.61% |
Ownership
| Insider Ownership | 41.74% |
| Institutional Ownership | 10.16% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.65 |
| P/B | 1.05 |
Analyst Data
| Recommendation | none |
| Target Price | $30.00 |
Technical Indicators
| SMA20 | $8.41 |
| SMA50 | $7.36 |
| SMA200 | $20.81 |
| RSI | 14.24 |
| ATR | 0.8207 |
| Shares Float | 818K |
| Short Float | 6.10% |
| Short Ratio | 0.01 |
| Rel Volume | 0.47 |
Performance History
| Week | -5.49% |
| Month | -45.85% |
| Quarter | -8.15% |
| 6 Months | -81.07% |
| YTD | -78.62% |
| Year | -90.20% |
| 3 Years | -99.23% |
| 5 Years | -99.99% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $6.20 | 34,500 |
| 2026-06-17 | $5.89 | 389,800 |
| 2026-06-16 | $6.10 | 26,000 |
| 2026-06-15 | $6.30 | 20,100 |
| 2026-06-12 | $6.15 | 28,000 |
| 2026-06-11 | $6.56 | 25,400 |
| 2026-06-10 | $6.34 | 43,100 |
| 2026-06-09 | $6.80 | 57,000 |
| 2026-06-08 | $7.39 | 40,000 |
| 2026-06-05 | $7.89 | 36,800 |
| 2026-06-04 | $8.19 | 59,500 |
| 2026-06-03 | $8.01 | 44,400 |
| 2026-06-02 | $8.00 | 54,500 |
| 2026-06-01 | $9.12 | 93,600 |
| 2026-05-29 | $10.57 | 50,900 |
| 2026-05-28 | $11.66 | 70,600 |
| 2026-05-27 | $11.14 | 55,000 |
| 2026-05-26 | $11.43 | 79,800 |
| 2026-05-22 | $11.99 | 83,500 |
| 2026-05-21 | $12.46 | 179,700 |
| 2026-05-20 | $11.40 | 78,600 |
| 2026-05-19 | $11.45 | 77,800 |
About Ernexa Therapeutics Inc.
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
đ° Latest News
ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know
Zacks âĸ 2026-05-20T14:45:00Z
Trump Rattled Markets Again and These 3 Forgotten Stocks Under $30 Were the Unlikely Winners
24/7 Wall St. âĸ 2026-05-18T14:35:31Z
Ernexa Therapeutics (ERNA) Preclinical Data Shows 100% Survival and Complete Tumor Clearance in Ovarian Cancer Models
InvestorsHub âĸ 2026-05-06T14:40:59Z
BC-Most Active Stocks
Associated Press Finance âĸ 2025-10-29T14:30:19ZErnexa Therapeutics First Half 2025 Earnings: US$2.91 loss per share (vs US$33.78 loss in 1H 2024)
Simply Wall St. âĸ 2025-08-15T11:55:01Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $0 | $96,000 | $236,000 | $0 |
| Cost Of Revenue | $0 | $96,000 | $236,000 | $0 |
| Total Revenue | $0 | $582,000 | $68,000 | $0 |
| Operating Revenue | $0 | $582,000 | $68,000 | $0 |
| Expenses | ||||
| Interest Expense | $27,000 | $6,752,000 | $614,000 | $30,000 |
| Total Expenses | $9,319,000 | $17,832,000 | $20,743,000 | $26,947,000 |
| Rent Expense Supplemental | $29,000 | $5,074,000 | $3,306,000 | $640,000 |
| Other Income Expense | $-4,866,000 | $-20,756,000 | $-520,000 | $2,443,000 |
| Other Non Operating Income Expenses | $215,000 | $70,000 | $-334,000 | $-1,141,000 |
| Net Non Operating Interest Income Expense | $56,000 | $-6,503,000 | $-476,000 | $-30,000 |
| Interest Expense Non Operating | $27,000 | $6,752,000 | $614,000 | $30,000 |
| Operating Expense | $9,319,000 | $17,736,000 | $20,507,000 | $26,947,000 |
| General And Administrative Expense | $5,163,000 | $13,132,000 | $14,587,000 | $16,555,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-14,084,000 | $-44,539,000 | $-21,668,000 | $-24,579,000 |
| Net Interest Income | $56,000 | $-6,503,000 | $-476,000 | $-30,000 |
| Interest Income | $83,000 | $249,000 | $138,000 | $0 |
| Normalized Income | $-9,018,751 | $-28,086,460 | $-21,482,019 | $-27,410,360 |
| Net Income From Continuing And Discontinued Operation | $-14,084,000 | $-44,539,000 | $-21,668,000 | $-24,579,000 |
| Total Operating Income As Reported | $-9,319,000 | $-15,674,000 | $-21,135,000 | $-33,217,000 |
| Net Income Common Stockholders | $-14,100,000 | $-44,555,000 | $-21,684,000 | $-24,595,000 |
| Net Income | $-14,084,000 | $-44,539,000 | $-21,668,000 | $-24,579,000 |
| Net Income Including Noncontrolling Interests | $-14,084,000 | $-44,539,000 | $-21,668,000 | $-24,579,000 |
| Net Income Continuous Operations | $-14,084,000 | $-44,539,000 | $-21,668,000 | $-24,579,000 |
| Pretax Income | $-14,129,000 | $-44,509,000 | $-21,671,000 | $-24,534,000 |
| Special Income Charges | $765,000 | $-20,798,000 | $-342,000 | $-6,270,000 |
| Interest Income Non Operating | $83,000 | $249,000 | $138,000 | $0 |
| Operating Income | $-9,319,000 | $-17,250,000 | $-20,675,000 | $-26,947,000 |
| Gross Profit | $0 | $486,000 | $-168,000 | $0 |
| Per Share | ||||
| Diluted EPS | $-56.00 | $-1224.00 | $-1530.00 | $-3022.50 |
| Basic EPS | $-56.00 | $-1224.00 | $-1530.00 | $-3022.50 |
| Other | ||||
| Tax Effect Of Unusual Items | $-15,751 | $-4,373,460 | $-19 | $752,640 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-8,758,000 | $-15,293,000 | $-19,748,000 | $-27,591,000 |
| Total Unusual Items | $-5,081,000 | $-20,826,000 | $-186,000 | $3,584,000 |
| Total Unusual Items Excluding Goodwill | $-5,081,000 | $-20,826,000 | $-186,000 | $3,584,000 |
| Reconciled Depreciation | $263,000 | $1,638,000 | $1,123,000 | $497,000 |
| EBITDA (Bullshit earnings) | $-13,839,000 | $-36,119,000 | $-19,934,000 | $-24,007,000 |
| EBIT | $-14,102,000 | $-37,757,000 | $-21,057,000 | $-24,504,000 |
| Diluted Average Shares | $252,280 | $36,400 | $14,170 | $8,136 |
| Basic Average Shares | $252,280 | $36,400 | $14,170 | $8,136 |
| Diluted NI Availto Com Stockholders | $-14,100,000 | $-44,555,000 | $-21,684,000 | $-24,595,000 |
| Preferred Stock Dividends | $16,000 | $16,000 | $16,000 | $16,000 |
| Tax Provision | $-45,000 | $30,000 | $-3,000 | $45,000 |
| Other Special Charges | $-765,000 | $20,864,000 | $460,000 | - |
| Restructuring And Mergern Acquisition | $0 | $-66,000 | $-118,000 | $0 |
| Gain On Sale Of Security | $-5,846,000 | $-28,000 | $156,000 | $9,854,000 |
| Research And Development | $4,156,000 | $4,604,000 | $5,920,000 | $10,392,000 |
| Selling General And Administration | $5,163,000 | $13,132,000 | $14,587,000 | $16,555,000 |
| Other Gand A | $2,001,000 | $4,523,000 | $7,088,000 | $9,336,000 |
| Insurance And Claims | $269,000 | $497,000 | $1,140,000 | $1,951,000 |
| Rent And Landing Fees | $29,000 | $5,074,000 | $3,306,000 | $640,000 |
| Salaries And Wages | $2,864,000 | $3,038,000 | $3,053,000 | $4,628,000 |
| Gain On Sale Of Ppe | - | - | $-1,000 | $-280,000 |
| Write Off | - | - | $0 | $5,990,000 |
| Other Taxes | - | - | - | - |
Fetched: 2026-06-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $357,000 | $-343,000 | $189,000 | $10,063,000 |
| Total Assets | $5,834,000 | $5,269,000 | $49,132,000 | $22,279,000 |
| Total Non Current Assets | $2,701,000 | $2,917,000 | $39,533,000 | $8,598,000 |
| Other Non Current Assets | $110,000 | $118,000 | $4,215,000 | $5,229,000 |
| Goodwill And Other Intangible Assets | $2,044,000 | $2,044,000 | $2,044,000 | $2,044,000 |
| Current Assets | $3,133,000 | $2,352,000 | $9,599,000 | $13,681,000 |
| Other Current Assets | $404,000 | $186,000 | $1,599,000 | $1,284,000 |
| Receivables | $845,000 | $437,000 | $425,000 | $951,000 |
| Other Receivables | $95,000 | $437,000 | $425,000 | $951,000 |
| Cash Cash Equivalents And Short Term Investments | $1,884,000 | $1,729,000 | $7,575,000 | $11,446,000 |
| Cash And Cash Equivalents | $1,884,000 | $1,729,000 | $7,575,000 | $11,446,000 |
| Cash Financial | $1,884,000 | $1,729,000 | $7,575,000 | $11,446,000 |
| Prepaid Assets | - | - | - | $1,284,000 |
| Non Current Prepaid Assets | - | - | - | - |
| Other Intangible Assets | - | - | - | - |
| Accounts Receivable | - | - | - | - |
| Debt | ||||
| Total Debt | $490,000 | $684,000 | $41,843,000 | $1,182,000 |
| Long Term Debt And Capital Lease Obligation | $277,000 | $477,000 | $39,627,000 | $887,000 |
| Current Debt And Capital Lease Obligation | $213,000 | $207,000 | $2,216,000 | $295,000 |
| Long Term Debt | - | - | $6,773,000 | $1,206,000 |
| Current Debt | - | - | - | $1,750,000 |
| Other Current Borrowings | - | - | - | $1,750,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $3,433,000 | $3,568,000 | $46,899,000 | $10,172,000 |
| Total Non Current Liabilities Net Minority Interest | $320,000 | $630,000 | $40,326,000 | $2,518,000 |
| Other Non Current Liabilities | $43,000 | $152,000 | $191,000 | $94,000 |
| Derivative Product Liabilities | $0 | $1,000 | $116,000 | $331,000 |
| Current Liabilities | $3,113,000 | $2,938,000 | $6,573,000 | $7,654,000 |
| Other Current Liabilities | $124,000 | - | - | $363,000 |
| Payables And Accrued Expenses | $2,764,000 | $2,719,000 | $4,058,000 | $5,931,000 |
| Payables | $1,878,000 | $1,724,000 | $2,274,000 | $3,370,000 |
| Total Tax Payable | $3,000 | $3,000 | $2,000 | $0 |
| Income Tax Payable | $3,000 | $3,000 | $2,000 | $0 |
| Accounts Payable | $1,125,000 | $1,721,000 | $1,067,000 | $1,620,000 |
| Non Current Deferred Liabilities | - | $0 | $392,000 | $0 |
| Current Deferred Liabilities | - | $0 | $190,000 | $0 |
| Interest Payable | - | $0 | $176,000 | $0 |
| Tradeand Other Payables Non Current | - | - | $0 | $0 |
| Current Notes Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $2,400,000 | $1,700,000 | $2,232,000 | $12,106,000 |
| Preferred Stock Equity | $1,000 | $1,000 | $1,000 | $1,000 |
| Total Equity Gross Minority Interest | $2,401,000 | $1,701,000 | $2,233,000 | $12,107,000 |
| Stockholders Equity | $2,401,000 | $1,701,000 | $2,233,000 | $12,107,000 |
| Retained Earnings | $-245,636,000 | $-231,536,000 | $-186,981,000 | $-165,297,000 |
| Long Term Equity Investment | - | - | $0 | $59,000 |
| Other | ||||
| Ordinary Shares Number | $314,160 | $137,029 | $14,427 | $13,672 |
| Share Issued | $314,160 | $137,029 | $14,427 | $13,672 |
| Tangible Book Value | $356,000 | $-344,000 | $188,000 | $10,062,000 |
| Invested Capital | $2,400,000 | $1,700,000 | $9,005,000 | $12,106,000 |
| Working Capital | $20,000 | $-586,000 | $3,026,000 | $6,027,000 |
| Capital Lease Obligations | $490,000 | $684,000 | $35,070,000 | $1,182,000 |
| Total Capitalization | $2,401,000 | $1,701,000 | $9,006,000 | $12,107,000 |
| Additional Paid In Capital | $247,997,000 | $233,219,000 | $189,186,000 | $177,377,000 |
| Capital Stock | $40,000 | $18,000 | $28,000 | $27,000 |
| Common Stock | $39,000 | $17,000 | $27,000 | $26,000 |
| Preferred Stock | $1,000 | $1,000 | $1,000 | $1,000 |
| Long Term Capital Lease Obligation | $277,000 | $477,000 | $32,854,000 | $887,000 |
| Current Capital Lease Obligation | $213,000 | $207,000 | $2,216,000 | $295,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $12,000 | $12,000 | $109,000 | $1,065,000 |
| Current Accrued Expenses | $886,000 | $995,000 | $1,784,000 | $2,561,000 |
| Dueto Related Parties Current | $750,000 | $0 | $1,205,000 | $1,750,000 |
| Goodwill | $2,044,000 | $2,044,000 | $2,044,000 | $2,044,000 |
| Net PPE | $547,000 | $755,000 | $33,274,000 | $1,266,000 |
| Accumulated Depreciation | $-197,000 | $-172,000 | $-114,000 | $-32,000 |
| Gross PPE | $744,000 | $927,000 | $33,388,000 | $1,298,000 |
| Leases | $68,000 | $0 | $274,000 | $0 |
| Other Properties | $458,000 | $698,000 | $32,821,000 | $1,058,000 |
| Machinery Furniture Equipment | $218,000 | $229,000 | $293,000 | $240,000 |
| Properties | $0 | $0 | $0 | $0 |
| Duefrom Related Parties Current | $750,000 | $0 | - | - |
| Non Current Deferred Revenue | - | $0 | $392,000 | $0 |
| Current Deferred Revenue | - | $0 | $190,000 | $0 |
| Dueto Related Parties Non Current | - | - | $0 | $1,206,000 |
| Investments And Advances | - | - | $0 | $59,000 |
Fetched: 2026-06-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-7,054,000 | $-16,205,000 | $-20,427,000 | $-21,273,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-7,017,000 | $-15,836,000 | $-20,408,000 | $-20,976,000 |
| Cash Flow From Continuing Operating Activities | $-7,017,000 | $-15,836,000 | $-20,408,000 | $-20,976,000 |
| Operating Gains Losses | $5,094,000 | $23,485,000 | $-203,000 | $-10,515,000 |
| Investing Activities | ||||
| Capital Expenditure | $-37,000 | $-369,000 | $-19,000 | $-297,000 |
| Investing Cash Flow | $-37,000 | $-365,000 | $-19,000 | $-47,000 |
| Cash Flow From Continuing Investing Activities | $-37,000 | $-365,000 | $-19,000 | $-47,000 |
| Net Other Investing Changes | - | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $4,929,000 | $1,137,000 | $320,000 | $19,706,000 |
| Financing Cash Flow | $7,209,000 | $6,260,000 | $16,556,000 | $19,579,000 |
| Cash Flow From Continuing Financing Activities | $7,209,000 | $6,260,000 | $16,556,000 | $19,579,000 |
| Net Common Stock Issuance | $4,929,000 | $1,137,000 | $320,000 | $19,706,000 |
| Common Stock Issuance | $4,929,000 | $1,137,000 | $320,000 | $19,706,000 |
| Net Other Financing Charges | - | $-169,000 | $-251,000 | $-116,000 |
| Cash Dividends Paid | - | $0 | $-16,000 | $-16,000 |
| Preferred Stock Dividend Paid | - | $0 | $-16,000 | $-16,000 |
| Net Preferred Stock Issuance | - | $1,137,000 | $0 | - |
| Preferred Stock Issuance | - | $1,137,000 | $0 | - |
| Other | ||||
| Issuance Of Debt | $2,250,000 | $5,292,000 | $18,003,000 | $0 |
| Interest Paid Supplemental Data | $6,000 | $48,000 | $20,000 | $30,000 |
| Income Tax Paid Supplemental Data | $3,000 | $3,000 | $4,000 | $15,000 |
| End Cash Position | $1,884,000 | $1,729,000 | $11,670,000 | $15,541,000 |
| Beginning Cash Position | $1,729,000 | $11,670,000 | $15,541,000 | $16,985,000 |
| Changes In Cash | $155,000 | $-9,941,000 | $-3,871,000 | $-1,444,000 |
| Proceeds From Stock Option Exercised | $30,000 | $0 | $0 | $7,000 |
| Net Issuance Payments Of Debt | $2,250,000 | $5,292,000 | $16,503,000 | $-2,000 |
| Net Long Term Debt Issuance | $2,250,000 | $5,292,000 | $16,503,000 | $-2,000 |
| Long Term Debt Issuance | $2,250,000 | $5,292,000 | $18,003,000 | $0 |
| Net PPE Purchase And Sale | $-37,000 | $-365,000 | $-19,000 | $-47,000 |
| Sale Of PPE | $0 | $4,000 | $0 | $250,000 |
| Purchase Of PPE | $-37,000 | $-369,000 | $-19,000 | $-297,000 |
| Change In Working Capital | $-51,000 | $-1,975,000 | $-2,117,000 | $3,710,000 |
| Change In Other Current Liabilities | $-193,000 | $-1,680,000 | $964,000 | $-185,000 |
| Change In Other Current Assets | $8,000 | $2,000 | $1,014,000 | $-646,000 |
| Change In Payables And Accrued Expense | $810,000 | $-1,022,000 | $-4,648,000 | $4,990,000 |
| Change In Payable | $810,000 | $-1,022,000 | $-4,648,000 | $4,990,000 |
| Change In Account Payable | $60,000 | $183,000 | $-2,898,000 | $2,034,000 |
| Change In Prepaid Assets | $-268,000 | $1,319,000 | $-556,000 | $-187,000 |
| Change In Receivables | $-408,000 | $-12,000 | $527,000 | $-262,000 |
| Other Non Cash Items | $232,000 | $5,052,000 | $1,215,000 | $214,000 |
| Stock Based Compensation | $1,496,000 | $1,520,000 | $1,242,000 | $2,935,000 |
| Unrealized Gain Loss On Investment Securities | $0 | $-1,017,000 | $0 | - |
| Asset Impairment Charge | $33,000 | $0 | $0 | $6,762,000 |
| Depreciation Amortization Depletion | $263,000 | $1,638,000 | $1,123,000 | $497,000 |
| Depreciation And Amortization | $263,000 | $1,638,000 | $1,123,000 | $497,000 |
| Depreciation | $263,000 | $1,638,000 | $1,123,000 | $497,000 |
| Gain Loss On Investment Securities | $5,846,000 | $1,045,000 | $-215,000 | $-10,795,000 |
| Gain Loss On Sale Of PPE | $13,000 | $0 | $1,000 | $280,000 |
| Net Income From Continuing Operations | $-14,084,000 | $-44,539,000 | $-21,668,000 | $-24,579,000 |
| Repayment Of Debt | - | $0 | $-1,500,000 | $-2,000 |
| Net Short Term Debt Issuance | - | $3,887,000 | $0 | $0 |
| Short Term Debt Issuance | - | $3,887,000 | $0 | $0 |
| Long Term Debt Payments | - | $0 | $-1,500,000 | $-2,000 |
| Change In Other Working Capital | - | $-582,000 | $582,000 | - |
| Gain Loss On Sale Of Business | - | $0 | $11,000 | - |
| Net Business Purchase And Sale | - | - | - | $0 |
| Sale Of Business | - | - | - | $0 |
| Purchase Of Business | - | - | - | $0 |
| Changes In Account Receivables | - | - | - | - |
Fetched: 2026-06-15